US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Curium
Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs
September 14, 2026
From
Curium
Via
GlobeNewswire
Curium acquires Abscint SA, expanding PET radiodiagnostic pipeline in oncology
August 10, 2026
From
Curium
Via
GlobeNewswire
Curium Announces Definitive Agreement to Merge with Lantheus
August 03, 2026
From
Curium
Via
GlobeNewswire
Tickers
LNTH
Curium, in collaboration with nuclear cardiology leaders, announces immediate return of Thallous Chloride TI 201 Injection in the U.S. to support high-stakes cardiac imaging needs
July 27, 2026
From
Curium
Via
GlobeNewswire
Court victory paves the way for Curium’s plans to provide targeted radioligand therapy to U.S. patients with GEP-NETs
June 18, 2026
From
Curium
Via
GlobeNewswire
Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
June 11, 2026
From
Curium
Via
GlobeNewswire
Curium Announces a Strategic Investment of Over €32 million in Saclay, France
June 01, 2026
From
Curium
Via
GlobeNewswire
Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026
February 26, 2026
From
Curium
Via
GlobeNewswire
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan
February 04, 2026
From
Curium
Via
GlobeNewswire
CapVest recapitalizes Curium to accelerate its growth strategy, marking the largest transaction in nuclear medicine globally
November 20, 2025
From
Curium
Via
GlobeNewswire
Curium Consolidates New Biopharma Business and Sets Up Global Headquarters in Boston, Massachusetts
November 17, 2025
From
Curium
Via
GlobeNewswire
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
October 15, 2025
From
Curium
Via
GlobeNewswire
Curium and NRG PALLAS extend collaboration in the supply of essential medical isotope to hospitals
May 21, 2025
From
Curium
Via
GlobeNewswire
Curium strengthens its PET manufacturing capacity and expands European footprint with the acquisition of Nucleis
April 10, 2025
From
Curium
Via
GlobeNewswire
Curium Announces Approval of Generic DTPA - Kit for the Preparation of Technetium Tc 99m Pentetate Injection in the U.S.
April 02, 2025
From
Curium
Via
GlobeNewswire
Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint
March 28, 2025
From
Curium
Via
GlobeNewswire
Curium Completes Enrollment Early of Phase 3 SOLAR-RECUR Prostate Cancer Trial
November 19, 2024
From
Curium
Via
GlobeNewswire
Curium Announces ECLIPSE Trial Has Met Primary Endpoint, Demonstrating a Statistically Significant and Clinically Meaningful Benefit for Patients With PSMA-Positive Metastatic Castration Resistant Prostate Cancer
November 13, 2024
From
Curium
Via
GlobeNewswire
Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan
October 01, 2024
From
Curium
Via
GlobeNewswire
Curium Announces the Official Opening its New Netherlands Facility for the Production of Lutetium-177 – a Game Changer Therapy Isotope for Cancer Patients Worldwide
September 24, 2024
From
Curium
Via
GlobeNewswire
Curium Submits New Drug Application for Lutetium Lu 177 Dotatate Injection
July 09, 2024
From
Curium
Via
GlobeNewswire
Curium Adds the Institut Laue-Langevin Reactor to Global Irradiation Portfolio to Ensure Continuous Supply of Lutetium-177 to Benefit More Than 100,000 Cancer Patients Over the Next 5 Years
June 05, 2024
From
Curium
Via
GlobeNewswire
Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-Psma Pet Tracer Indicated in Patients With Prostate Cancer
May 30, 2024
From
Curium
Via
GlobeNewswire
Curium Extends Irradiation Partnership With NRG I PALLAS in Netherlands for Continuous Supply of Lutetium-177 to Treat 1,000s of Cancer Patients Each Year
May 29, 2024
From
Curium
Via
GlobeNewswire
Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials
April 23, 2024
From
Curium
Via
GlobeNewswire
Curium Plans to Significantly Expand Lutetium-177 Capacity and Pet Footprint With Agreement to Acquire Eczacibaşi-Monrol
April 08, 2024
From
Curium
Via
GlobeNewswire
Curium Announces Ioflupane I 123 Injection Availability for Friday Patient Use
February 06, 2024
From
Curium
Via
GlobeNewswire
Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule
November 23, 2023
From
Curium
Via
GlobeNewswire
Curium Announces First Patients in Europe Injected With PYLCLARI® – an Innovative 18F-PSMA Pet Tracer Indicated in Patients With Prostate Cancer
November 16, 2023
From
Curium
Via
GlobeNewswire
Curium and PIUR IMAGING Announce Thyroid Imaging Partnership in Germany to Enable Tomographic 3D Ultrasound Solutions
October 25, 2023
From
Curium
Via
GlobeNewswire
